| Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study T Powles, PH O'Donnell, C Massard, HT Arkenau, TW Friedlander, ... JAMA oncology 3 (9), e172411-e172411, 2017 | 918 | 2017 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 549* | 2021 |
| Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ... Clinical Cancer Research 21 (20), 4586-4596, 2015 | 202 | 2015 |
| Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK AW Tolcher, K Khan, M Ong, U Banerji, V Papadimitrakopoulou, ... Clinical Cancer Research 21 (4), 739-748, 2015 | 141 | 2015 |
| Unscheduled return visits to the pediatric emergency department-one-year experience RD Goldman, M Ong, A Macpherson Pediatric emergency care 22 (8), 545-549, 2006 | 130 | 2006 |
| First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014 B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ... Clinical cancer research 21 (15), 3412-3419, 2015 | 127 | 2015 |
| First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. JS De Bono, LA Mina, M Gonzalez, NJ Curtin, E Wang, JW Henshaw, ... Journal of Clinical Oncology 31 (15_suppl), 2580-2580, 2013 | 107 | 2013 |
| Appraising iniparib, the PARP inhibitor that never was—what must we learn? J Mateo, M Ong, DSP Tan, MA Gonzalez, JS De Bono Nature reviews Clinical oncology 10 (12), 688-696, 2013 | 106 | 2013 |
| Antitumor activity of nivolumab on hemodialysis after renal allograft rejection M Ong, AM Ibrahim, S Bourassa-Blanchette, C Canil, T Fairhead, G Knoll Journal for ImmunoTherapy of Cancer 4, 1-5, 2016 | 85 | 2016 |
| The effects of economic reform on health insurance and the financial burden for urban workers in China TW Hu, M Ong, ZH Lin, E Li Health Economics 8 (4), 309-321, 1999 | 79 | 1999 |
| OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors M Gutierrez, V Moreno, KM Heinhuis, AJ Olszanski, A Spreafico, M Ong, ... Clinical Cancer Research 27 (2), 460-472, 2021 | 65 | 2021 |
| SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ... Anaesthesia 77 (1), 28-39, 2022 | 59 | 2022 |
| Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma. T Powles, PH O'Donnell, C Massard, HT Arkenau, TW Friedlander, ... Journal of Clinical Oncology 35 (6_suppl), 286-286, 2017 | 59 | 2017 |
| A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer M Clemons, M Ong, C Stober, S Ernst, C Booth, C Canil, M Mates, ... European Journal of Cancer 142, 132-140, 2021 | 56 | 2021 |
| Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review R Fernandes, S Mazzarello, B Hutton, R Shorr, H Majeed, MFK Ibrahim, ... Supportive Care in Cancer 24, 3633-3650, 2016 | 55 | 2016 |
| AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer–results of two parallel first-in-human phase I studies A Omlin, RJ Jones, R Van Der Noll, T Satoh, M Niwakawa, SA Smith, ... Investigational new drugs 33, 679-690, 2015 | 55 | 2015 |
| Using a knowledge translation framework to implement asthma clinical practice guidelines in primary care C Licskai, T Sands, M Ong, L Paolatto, I Nicoletti International Journal for Quality in Health Care 24 (5), 538-546, 2012 | 52 | 2012 |
| Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, ... Annals of Oncology 32 (7), 896-905, 2021 | 49 | 2021 |
| Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). NM Hahn, T Powles, C Massard, HT Arkenau, TW Friedlander, CJ Hoimes, ... Journal of Clinical Oncology 35 (15_suppl), 4525-4525, 2017 | 43 | 2017 |
| Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ... Anaesthesia 76 (11), 1454-1464, 2021 | 42 | 2021 |
